The statements below are read from Bharat Immunologicals & Biologicals Corporation Ltd’s filed results, 0 filed quarters and 12 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: FY22-23 · filed Mar 31, 2023 · audited
Sales CAGR · 3Y−12.4%FY19 → FY22
Sales CAGR · 4Y−14.4%FY18 → FY22
PAT CAGR · 3Y—FY19 → FY22
PAT CAGR · 4Y—FY18 → FY22
Price · 1Y—EOD
Price CAGR · 3Y—EOD
No quarterly filings yet
We haven't ingested quarterly results for BIBCL on the standalone basis yet.
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
